Shots:
- Replicate has entered into a multi-year research collaboration with Novo Nordisk to develop novel self-replicating RNA (srRNA) therapies for obesity, T2D & other cardiometabolic diseases, leveraging Replicate’s srRNA platform
- As per the deal, Novo & Replicate will collaborate on certain cardiometabolic targets, granting Novo an exclusive global license to Replicate’s srRNA platform to devlelop & commercialize lead programs in exchange for research funding & ~$550M, incl. upfront & milestones payment, plus tiered royalties
- Replicate’s srRNA platform allows customizable protein expression with superior durability, tunability, & higher in vivo expression compared with other RNA modalities
Ref: Replicate Bioscience| Image: Replicate Bioscience AND Novo Nordisk | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
